NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Follow-Up Questions
Who is the CEO of NextCure Inc?
Mr. Michael Richman is the President of NextCure Inc, joining the firm since 2015.
What is the price performance of NXTC stock?
The current price of NXTC is $5.66, it has increased 0.45% in the last trading day.
What are the primary business themes or industries for NextCure Inc?
NextCure Inc belongs to Biotechnology industry and the sector is Health Care
What is NextCure Inc market cap?
NextCure Inc's current market cap is $15.1M
Is NextCure Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for NextCure Inc, including 2 strong buy, 5 buy, 2 hold, 0 sell, and 2 strong sell
